ENDOMETRIOSIS 1990 - CURRENT TREATMENT APPROACHES

被引:39
作者
BARBIERI, RL [1 ]
机构
[1] HARVARD UNIV,SCH MED,HUMAN REPROD BIOL LAB,BOSTON,MA 02115
关键词
D O I
10.2165/00003495-199039040-00003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Endometriosis is an extremely common gynaecological disease, affecting between 1 and 5% of women of reproductive age. Women with endometriosis typically present for medical care with one of more of the following problems: pelvic pain, infertility, or a large adnexal mass (an endometrioma). The primary treatment for an endometrioma is surgical. However, long term postoperative hormone therapy may be necessary to prevent new endometriomas from developing. There is no evidence that hormonal therapy of endometriosis will improve fecundability in women with endometriosis and infertility. Pelvic pain due to endometriosis can be successfully treated with hormonal agents in the majority of patients. Four basic hormonal regimens are currently available for the treatment of endometriosis: (a) danazol; (b) gonadotrophin-releasing hormone (GnRH) [luteinising hormone-releasing hormone (LHRH); gonadorelin] agonists; (c) progestérones (progestins); and (d) combined estrogens and progesterones. Randomised, controlled, clinical trials suggest that danazol and the GnRH agonists are equally effective in the treatment of endometriosis. However, the side effects caused by danazol and the GnRH agonists are markedly different. Danazol produces androgenic side effects including weight gain, hirsutism, acne, oily skin and deepening of the voice. GnRH agonists produce side effects due to hypoestrogenism, including hot flushes, osteoporosis and dry vagina. The ideal drug regimen for the treatment of endometriosis remains to be developed. © 1990, ADIS Press Limited. All rights reserved.
引用
收藏
页码:502 / 510
页数:9
相关论文
共 25 条
[1]  
BARBIERI RL, 1979, FERTIL STERIL, V31, P182
[2]  
BARBIERI RL, 1982, FERTIL STERIL, V37, P737
[3]  
BARBIERI RL, 1986, FERTIL STERIL, V45, P630
[4]  
BARBIERI RL, 1977, FERTIL STERIL, V28, P809
[5]  
BARBIERI RL, 1981, AM J OBSTET GYNECOL, V141, P456
[6]  
BARBIERI RL, 1989, GYNECOLOGY FERTILITY, V12, P6
[7]   A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER [J].
BAST, RC ;
KLUG, TL ;
STJOHN, E ;
JENISON, E ;
NILOFF, JM ;
LAZARUS, H ;
BERKOWITZ, RS ;
LEAVITT, T ;
GRIFFITHS, CT ;
PARKER, L ;
ZURAWSKI, VR ;
KNAPP, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (15) :883-887
[8]   NAFARELIN - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND CLINICAL POTENTIAL IN SEX HORMONE-RELATED CONDITIONS [J].
CHRISP, P ;
GOA, KL .
DRUGS, 1990, 39 (04) :523-551
[9]  
CRAMER DW, 1987, ENDOMETRIOSIS, P5
[10]  
Crowley W F Jr, 1985, Recent Prog Horm Res, V41, P473